ASCO GUIDELINES Bundle

Metastatic HER2-Negative Breast Cancer – Chemo and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/1475478

Contents of this Issue

Navigation

Page 1 of 7

Introduction ➤ The purpose of this guideline update is to gather and examine the evidence published since the 2014 guideline a and offer a series of updated recommendations for advanced HER2-negative breast cancer, if warranted. ➤ Note that while this guideline provides recommendations for chemo- and targeted therapy for patients with HER2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative, a companion guideline b provides endocrine therapy and targeted therapy recommendations, including CDK 4/6 and PI3 kinase inhibition, for hormone receptor-positive metastatic breast cancer patients. a Partridge AH et al. J Clin Oncol. 2014 Oct 10;32(29):3307-29 b Burstein HJ et al. J Clin Oncol. 2021 July 29;39(35):3959-3977 Treatment New Recommendation from 2022 Guideline Rapid Recommendation Update ➤ Patients with HER2 IHC 1+ or 2+ and ISH negative metastatic breast cancer who have received at least one prior chemotherapy for metastatic disease, and if HR+ are refractory to endocrine therapy, should be offered treatment with trastuzumab deruxtecan. (Strong recommendation; EB-B-M)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Metastatic HER2-Negative Breast Cancer – Chemo and Targeted Therapy Either Endocrine-Pretreated or Hormone Receptor-Negative